Sandeep Mashru, MD
Hematology & Oncology · Portland, ORNPI 1629053855
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $644 of the $795 with a category attached, or 81.1%. Genentech USA, Inc. accounts for 98.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in OR, where the typical reported total is $847.
Across 3 payments — averaging $264.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$783
- E.r. Squibb & Sons, L.L.C.$12
Across 511 payments — averaging $9084.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.7M
- Merck$711K
- AstraZeneca$334K
- Genentech, Inc.$306K
- EMD Serono, Inc.$290K
- GSK$230K
- plus $1.1M from 14 others
What the payments were for
- Travel & lodging$64481%
- Food & beverage$13917%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 2 | $783 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$795 in reported general payments places this provider in the 45th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 98 | $1,750,516 |
| XtandiEnzalutamide | 76 | $816,598 |
| MekinistTrametinib Dimethyl Sulfoxide | 33 | $468,483 |
| TabrectaCapmatinib Hydrochloride | 23 | $462,347 |
| TafinlarDabrafenib Mesylate | 32 | $403,416 |
| RetevmoSelpercatinib | 22 | $281,129 |
| ZelborafVemurafenib | 28 | $256,819 |
| InlytaAxitinib | 13 | $240,526 |
| IbrancePalbociclib | 14 | $216,740 |
| CotellicCobimetinib Fumarate | 23 | $152,423 |
| LumakrasSotorasib | 17 | $148,116 |
| XermeloTelotristat Etiprate | 12 | $121,656 |
| Abiraterone Acetate | 152 | $42,171 |
| XareltoRivaroxaban | 22 | $21,351 |
| Anastrozole | 175 | $4,734 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Portland
- Brian DrukerPortland$1.9M
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Elie TraerPortland$72K
- Jeffrey MenashePortland$38K
- Michael HeinrichPortland$37K
- Lucy LangerPortland$18K
- Miklos SimonPortland$13K
- Alexandra SokolovaPortland$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.